西南医科大学学报2024，Vol.47Issue(4)：321-324,4.DOI:10.3969/j.issn.2096-3351.2024.04.009
大黄蛰虫丸加减联合奥拉帕利治疗乳腺癌基因突变型卵巢癌
Modified Dahuang Zhechong Pill combined with Olaparib for the treatment of ovarian cancer with breast cancer gene mutations
摘要
Abstract
Objective To analyze the efficacy of modified Dahuang Zhechong pill combined with olaparib tablets in ovarian can-cer patients with BRCA mutations and its impact on carcinoembryonic antigen(CEA)、carbohydrate antigen 125(CA125)、carbohydrate antigen 199(CA199)levels.Methods Clinical data of 98 patients with ovarian cancer underwent surgical treatment in our hospital from February 2021 to February 2023 were retrospectively analyzed.Patients were redivided into two groups for different treatment regimes,each with 49 cases.Control group received olaparib tablets,while observation group received modified Dahuang Zhechong pill com-bined with olaparib tablets.Then the clinical efficacy,tumor markers(CEA,CA125,CA199)and adverse drug reactions were observed in both groups.Results Serum levels of CEA,CA125 and CA199 were notably lower in the observation group than in the control group(P<0.05).The incidence of nausea,liver and kidney dysfunction and pain in the observation group were lower than those in the con-trol group(P<0.05).Before treatment,there was no statistically significant difference in the scores of traditional Chinese medicine symptoms(abdominal bloating and pain,poor appetite,and dull complexion)between the two groups(P>0.05);after treatment,the scores for abdominal bloating and pain,poor appetite,and dull complexion decreased in both groups,and the scores in the observation group were lower than those in the control group(P<0.05).The effective rate of western medical treatment(83.67%)in the observa-tion group was higher than that in the control group(55.10%)(P<0.05).The effective rate of traditional Chinese medicine treatment in the control group(53.06%)was lower than that in the observation group(83.67%)(P<0.05).Conclusion The combination of Da-huang Zhechong pill with olaparib for the treatment of BRCA-mutated breast cancer could improve clinical efficacy and reduce adverse drug reactions.关键词
卵巢癌/BRCA突变/危险因素/大黄蛰虫丸/奥拉帕利Key words
Ovarian cancer/BRCA mutation/Risk factors/Dahuang Zhechong Pill/Olaparib分类
医药卫生引用本文复制引用
梁爽,赵威,陈丽,丁瑞敏,王晖..大黄蛰虫丸加减联合奥拉帕利治疗乳腺癌基因突变型卵巢癌[J].西南医科大学学报,2024,47(4):321-324,4.基金项目
河南省中医药科学研究专项课题(20-21ZY2220) （20-21ZY2220）
